Alicia Molinier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alicia Molinier has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alison C. Johnson
Medical Oncology Department, Centre Francois Baclesse, Caen, France
1 shared publication Audrey Emmanuelle Dugué
Centre François Baclesse, F-14000 Caen, France
1 shared publication- Bernard Escudier
Department of Oncology, Institute Gustave Roussy, Villejuif, France
1 shared publication Blandine Acket
CHU de Toulouse, hôpital Purpan, service de neurologie, 31300 Toulouse, France
1 shared publication- Brigitte Laguerre
Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France
1 shared publication - Carole Helissey
Department of Medical Oncology, Bégin Military Hospital, 94160 Saint‑Mandé, Ile de France, France
1 shared publication
Latest Publications
- Open Access
- 22 May 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 355
Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect is the increase of haemoglobin level (HbL) during treatment with a suspected correlation with better outcome. Our objective was to examine whether HbL increase during the first three months of axitinib treatment is associated with better prognosis. Retrospective multicentre analysis including patients with mRCC treated with axitinib for at least three months from 2012 to 2014. Progression-free survival (PFS) was analysed by a Cox model according to gender, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic score, high blood pressure (hBP), and maximum increase in HbL within the first three months of treatment. Ninety-eight patients were analysed (71% men; median age at treatment initiation: 62 years; IMDC: 24%, 50%, and 26% in the favourable, intermediate, and poor-risk group, respectively). Patients received axitinib for a median of 8 months. During the first three months, the median increase of HbL was +2.3 g/dL (−1.1; 7.2). Fifty-six (57%) patients developed hBP. In multivariate analysis, after adjustment for performance status (P < 0.0001) and gender (P = 0.0041), the combination of HbL increase ≥2.3 g/dL and any grade hBP was significantly associated with longer PFS (HR = 0.40, 95%CI [0.24; 0.68]). Early HbL increase during axitinib treatment combined with hBP is an independent predictive factor of PFS. These results require validation in a prospective setting.
- 22 May 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 355
Open AccessHaemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect is the increase of haemoglobin level (HbL) during treatment with a suspected correlation with better outcome. Our objective was to examine whether HbL increase during the first three months of axitinib treatment is associated with better prognosis. Retrospective multicentre analysis including patients with mRCC treated with axitinib for at least three months from 2012 to 2014. Progression-free survival (PFS) was analysed by a Cox model according to gender, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic score, high blood pressure (hBP), and maximum increase in HbL within the first three months of treatment. Ninety-eight patients were analysed (71% men; median age at treatment initiation: 62 years; IMDC: 24%, 50%, and 26% in the favourable, intermediate, and poor-risk group, respectively). Patients received axitinib for a median of 8 months. During the first three months, the median increase of HbL was +2.3 g/dL (−1.1; 7.2). Fifty-six (57%) patients developed hBP. In multivariate analysis, after adjustment for performance status (P < 0.0001) and gender (P = 0.0041), the combination of HbL increase ≥2.3 g/dL and any grade hBP was significantly associated with longer PFS (HR = 0.40, 95%CI [0.24; 0.68]). Early HbL increase during axitinib treatment combined with hBP is an independent predictive factor of PFS. These results require validation in a prospective setting.
- 1 April 2014
- Published by Elsevier in La Presse Médicale
- Vol. 43 (4) , 468-469
Extrapolation des données physiopathologiques à la pratique clinique : à propos du dabigatran utilisé hors AMM
- 1 April 2014
- Published by Elsevier in La Presse Médicale
- Vol. 43 (4) , 468-469
Extrapolation des données physiopathologiques à la pratique clinique : à propos du dabigatran utilisé hors AMM